Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial

[1] Haffner SM(1998)Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229-234

[2] Lehto S(2015)Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research World J Diabetes 6 1246-1258

[3] Rönnemaa T(2013)Atherogenic index of plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios) Karbala J Med 6 1506-1513

[4] Pyörälä K(2006)Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma J Cardiovasc Pharmacol 47 542-548

[5] Laakso M(2015)Comparative analysis of atherogenic index of plasma and its relationship with cardiovascular risk among patients with diabetes mellitus and concurrent diabetes mellitus with hypertension attending endocrinology clinic in a tertiary hospital south-south Nigeria Atherosclerosis 13 16-1206

[6] Leon BM(2015)Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with type 2 diabetes: a population-based case–control study Diabet Med 32 1201-404

[7] Maddox TM(2009)Blood pressure variables and cardiovascular risk: new findings from ADVANCE Hypertension 54 399-16

[8] Khazaal MS(1999)Dyslipidaemia in diabetes mellitus Prevalence 13 15-180

[9] Christodoulakos GE(1999)Diabetic dyslipidaemia Eur J Clin Investig 29 12-166

[10] Lambrinoudaki IV(1991)Pineal melatonin: cell biology of its synthesis and of its physiological interactions Endocr Rev 12 151-257

[1] Haffner SM(1998)Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229-234

[2] Lehto S(2015)Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research World J Diabetes 6 1246-1258

[3] Rönnemaa T(2013)Atherogenic index of plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios) Karbala J Med 6 1506-1513

[4] Pyörälä K(2006)Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma J Cardiovasc Pharmacol 47 542-548

[5] Laakso M(2015)Comparative analysis of atherogenic index of plasma and its relationship with cardiovascular risk among patients with diabetes mellitus and concurrent diabetes mellitus with hypertension attending endocrinology clinic in a tertiary hospital south-south Nigeria Atherosclerosis 13 16-1206

[6] Leon BM(2015)Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with type 2 diabetes: a population-based case–control study Diabet Med 32 1201-404

[7] Maddox TM(2009)Blood pressure variables and cardiovascular risk: new findings from ADVANCE Hypertension 54 399-16

[8] Khazaal MS(1999)Dyslipidaemia in diabetes mellitus Prevalence 13 15-180

[9] Christodoulakos GE(1999)Diabetic dyslipidaemia Eur J Clin Investig 29 12-166

[10] Lambrinoudaki IV(1991)Pineal melatonin: cell biology of its synthesis and of its physiological interactions Endocr Rev 12 151-257